Alentis is a clinical-stage biotech company developing anti-Claudin-1 therapies targeting solid tumors and fibrosis
Alentis is a clinical-stage biotech company developing anti-Claudin-1 therapies targeting solid tumors and fibrosis. The company focuses on monoclonal antibodies and antibody-drug conjugates to address unmet medical needs in patients with Claudin-1 positive conditions.